Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 646 to 660 of 729 results for diabet*

  1. Glitazones in the treatment of type 2 diabetes (TA63)

    This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).

    Withdrawn guidance

  2. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613)

    This guidance has been updated and replaced by NICE technology appraisal guidance 953.

    Withdrawn guidance

  3. Diabetes in pregnancy: Management of diabetes and its complications from pre-conception to the postnatal period (CG63)

    This guidance has been updated and replaced by NICE guideline NG3.

    Withdrawn guideline

  4. Type 2 diabetes (CG66)

    This guidance has been updated and replaced by NICE guideline NG28.

    Withdrawn guideline

  5. Diagnosis and management of type 1 diabetes in children, young people and adults (CG15)

    This guidance has been updated and replaced by NICE guidelines NG17, NG18 and NG19.

    Withdrawn guideline

  6. Diabetic foot problems: Inpatient management of diabetic foot problems (CG119)

    This guidance has been updated and replaced by NICE guideline NG19.

    Withdrawn guideline

  7. Type 2 diabetes foot problems: Prevention and management of foot problems (CG10)

    This guidance has been updated and replaced by NICE guideline NG19.

    Withdrawn guideline

  8. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Type 2 diabetes: dulaglutide (ESNM59)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Withdrawn advice

  10. Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM62)

    This evidence summary has been updated and replaced by NICE guideline NG17.

    Withdrawn advice

  11. Type 2 diabetes: empagliflozin (ESNM35)

    This evidence summary has been replaced by NICE technology appraisal guidance 336.

    Withdrawn advice

  12. Type 2 diabetes: insulin degludec (ESNM4)

    This evidence summary has been updated and replaced by NICE advice ESNM25.

    Withdrawn advice

  13. Type 1 diabetes: insulin degludec (ESNM5)

    This evidence summary has been updated and replaced by NICE advice ESNM24.

    Withdrawn advice

  14. Type 2 diabetes: lixisenatide (ESNM10)

    This evidence summary has been updated and replaced by NICE advice ESNM26.

    Withdrawn advice

  15. Type 2 diabetes: alogliptin (ESNM20)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Withdrawn advice